Tacrolimus Intra-patient Variability is Not Associated with Chronic Active Antibody Mediated Rejection
Overview
Authors
Affiliations
Background: Chronic active antibody mediated rejection (c-aABMR) is a major cause of long-term kidney allograft loss. It is hypothesized that frequent sub-therapeutic exposure to immunosuppressive drugs, in particular tacrolimus (Tac), is a risk factor for the development of c-aABMR. The intra-patient variability (IPV) in Tac exposure may serve as a substitute biomarker for underexposure and/or non-adherence. In this study, the association between Tac IPV and the development of c-aABMR was investigated.
Methods: We retrospectively included 59 patients diagnosed with c-aABMR and compared them to 189 control patients matched for age, year of transplantation and type of kidney donor. The Tac IPV was calculated from pre-dose tacrolimus concentrations measured over a 3 year period preceding the diagnosis of c-aABMR. The mean Tac predose concentrations (C0), Tac IPV, renal allograft function and graft survival were compared between the groups.
Results: Tac IPV was 24.4% for the cases versus 23.6% for the controls (p = 0.47). The mean Tac C0 was comparable for the cases (5.8 ng/mL) and control patients (6.1 ng/mL, p = 0.08). Only in the c-aABMR group a significant decline in both mean Tac C0 and allograft function over the timespan of 3 years was observed (p = 0.03 and p<0.001). Additionally, in the group of c-aABMR patients a high IPV was associated with inferior graft survival (p = 0.03).
Conclusions: A high Tac IPV per se does not predispose to the development of c-aABMR but is associated with inferior graft survival once c-aABMR is diagnosed.
Beland M, Lapointe I, Cote I, Lesage J, Houde I, Wagner E Front Immunol. 2024; 15:1493878.
PMID: 39635538 PMC: 11614807. DOI: 10.3389/fimmu.2024.1493878.
Baghai Arassi M, Feisst M, Krupka K, Awan A, Benetti E, Duzova A Kidney Int Rep. 2024; 9(11):3265-3277.
PMID: 39534206 PMC: 11551099. DOI: 10.1016/j.ekir.2024.08.025.
Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation.
Morais M, Soares M, Costa G, Guerra L, Vaz N, Codes L World J Transplant. 2023; 13(5):254-263.
PMID: 37746041 PMC: 10514747. DOI: 10.5500/wjt.v13.i5.254.
van den Broek D, Meziyerh S, Budde K, Lefaucheur C, Cozzi E, Bertrand D Transpl Int. 2023; 36:11321.
PMID: 37560072 PMC: 10408721. DOI: 10.3389/ti.2023.11321.
Betjes M, De Weerd A Front Med (Lausanne). 2023; 10:1215167.
PMID: 37502354 PMC: 10368955. DOI: 10.3389/fmed.2023.1215167.